RxDoctor Payments Data

Lauren Daub

Physician Assistant · Fort Worth, TXNPI 1962069443

Payments from drug & device makers

$8,992in general payments, 2019–2025

Across 470 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AstraZeneca$978
  • Amgen$853
  • Novo Nordisk$758
  • Dexcom, Inc.$703
  • Sanofi-aventis U.S. LLC$655
  • plus $4K from 42 others
$126in research payments, 2019–2025

Across 1 payment — averaging $126.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Corcept Therapeutics$126

What the payments were for

  • Food & beverage$8,981100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,992 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide119$168,077
MounjaroTirzepatide117$134,560
TymlosAbaloparatide27$95,398
Tresiba Flextouch U-100Insulin Degludec70$57,175
JardianceEmpagliflozin57$56,793
TrulicityDulaglutide41$48,302
Tresiba Flextouch U-200Insulin Degludec37$45,099
FarxigaDapagliflozin Propanediol47$35,001
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog47$32,415
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/712$28,170
RybelsusSemaglutide12$27,272
Xigduo XrDapaglifloz Propaned/Metformin13$16,207
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$14,987
SynthroidLevothyroxine Sodium168$14,260
JanuviaSitagliptin Phosphate21$11,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$758$201,099143 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$1,007$187,218180 claims
Radius Health, Inc.Tymlos$40$95,39827 claims
Boehringer IngelheimJardiance, Synjardy$286$66,23868 claims
AstraZenecaFarxiga$978$35,00147 claims
AbbVieSynthroid, Armour Thyroid$409$14,824180 claims
MerckJanuvia$53$11,00521 claims
IBSA Pharma Inc.Tirosint$85$2,80513 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$63$2,600283 claims
Sanofi-aventis U.S. LLCLantus$655$1,79814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →